Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindMaze Therapeutics HoldingXSWX:MMTX +3.67%4 Equity-to-Asset is 0.74 as of Dec. 2025, which is 11% below its 10-year median of 0.83. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, MindMaze Therapeutics Holding ranks better than 57.37% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MindMaze Therapeutics Holding Equity-to-Asset Related Terms
MindMaze Therapeutics Holding Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MMTX vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding (XSWX:MMTX) has a Equity-to-Asset of 0.74 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MindMaze Therapeutics Holding and its competitors. This is 11% below median its historical median of 0.83. Over the past decade, MindMaze Therapeutics Holding's Equity-to-Asset has ranged from 0.74 to 0.93. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #604 out of 1417 companies in the Biotechnology industry, placing it in the top 42.6%.
Is MindMaze Therapeutics Holding's Equity-to-Asset too high?
MindMaze Therapeutics Holding's current Equity-to-Asset of 0.74 is 11% below median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. MindMaze Therapeutics Holding's value of 0.74 is 8.8% above this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #604 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #604 out of 1417 companies for Equity-to-Asset. This puts MindMaze Therapeutics Holding in the upper half of its industry. The industry median Equity-to-Asset is 0.68. MindMaze Therapeutics Holding's value of 0.74 is 8.8% above this benchmark. Historically, MindMaze Therapeutics Holding's own Equity-to-Asset has ranged from 0.74 to 0.93 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.68, MindMaze Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Equity-to-Asset of 0.74 is 8.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Equity-to-Asset is 0.74, which is 11% below median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Equity-to-Asset of 0.74. The current Equity-to-Asset is 0.74, which is 11% below median its 10-year median of 0.83 and 8.8% above the Biotechnology industry median of 0.68. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Equity-to-Asset is 0.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
